WO2009108372A3 - Antibodies as t cell receptor mimics, methods of production and uses thereof - Google Patents
Antibodies as t cell receptor mimics, methods of production and uses thereof Download PDFInfo
- Publication number
- WO2009108372A3 WO2009108372A3 PCT/US2009/001290 US2009001290W WO2009108372A3 WO 2009108372 A3 WO2009108372 A3 WO 2009108372A3 US 2009001290 W US2009001290 W US 2009001290W WO 2009108372 A3 WO2009108372 A3 WO 2009108372A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- methods
- production
- cell receptor
- receptor mimics
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000006037 cell lysis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The presently disclosed and claimed invention relates to a methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies may be utilized in therapeutic methods of mediating cell lysis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09715242A EP2262834A4 (en) | 2008-02-27 | 2009-02-27 | Antibodies as t cell receptor mimics, methods of production and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6732808P | 2008-02-27 | 2008-02-27 | |
US61/067,328 | 2008-02-27 | ||
US19187108P | 2008-09-12 | 2008-09-12 | |
US61/191,871 | 2008-09-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009108372A2 WO2009108372A2 (en) | 2009-09-03 |
WO2009108372A3 true WO2009108372A3 (en) | 2009-11-05 |
Family
ID=41016658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/001290 WO2009108372A2 (en) | 2008-02-27 | 2009-02-27 | Antibodies as t cell receptor mimics, methods of production and uses thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2262834A4 (en) |
WO (1) | WO2009108372A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2651510T3 (en) | 2011-04-01 | 2018-01-26 | Memorial Sloan-Kettering Cancer Center | T-cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
PT3626729T (en) | 2014-12-23 | 2021-11-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
RU2021124437A (en) | 2015-04-03 | 2021-09-29 | Еурека Терапьютикс, Инк. | CONSTRUCTIONS AIMED AT THE AFP / MHC PEPTIDE COMPLEXES AND THEIR USES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060034850A1 (en) * | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090042285A1 (en) * | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007030451A2 (en) * | 2005-09-07 | 2007-03-15 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
CA2656583A1 (en) * | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
-
2009
- 2009-02-27 WO PCT/US2009/001290 patent/WO2009108372A2/en active Application Filing
- 2009-02-27 EP EP09715242A patent/EP2262834A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060034850A1 (en) * | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20070092530A1 (en) * | 2004-05-27 | 2007-04-26 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090042285A1 (en) * | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
WO2009108372A2 (en) | 2009-09-03 |
EP2262834A4 (en) | 2011-08-17 |
EP2262834A2 (en) | 2010-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL207449A0 (en) | Genetically modified cyanobacteria, methods of producing the same and methods of producing ethanol utilizing the same | |
IL216861A (en) | Nucleic acids encoding polypeptides that bind to activine, gdf8 or gdf11, cultured cells comprising them, polypeptides, pharmaceutical preparations and uses thereof | |
IL195470A0 (en) | Antibodies as t cell receptor mimics, methods of production and uses thereof | |
HRP20160730T1 (en) | Methods of modifying antibodies, and modified antibodies with improved functional properties | |
WO2013151666A3 (en) | Modified polynucleotides for the production of biologics and proteins associated with human disease | |
WO2010117957A3 (en) | Methods and materials for delivering molecules | |
WO2013152059A8 (en) | Multicolored ph-activatable fluorescence nanoplatform | |
WO2011062997A3 (en) | Human monoclonal antibodies to human nucleolin | |
WO2013021279A3 (en) | Highly galactosylated antibodies | |
NZ593314A (en) | Dual variable domain immunoglobulins and uses thereof | |
WO2013151665A3 (en) | Modified polynucleotides for the production of proteins associated with human disease | |
WO2011056644A3 (en) | Anti-glp-1r antibodies and their uses | |
WO2014012001A3 (en) | Use of cart19 to deplete normal b cells to induce tolerance | |
EP2286902A4 (en) | Separation membrane, method of producing the same and separation membrane module using the separation membrane | |
MY161909A (en) | Anti-her3 antibodies and uses thereof | |
WO2010040508A8 (en) | Bispecific anti-vegf/anti-ang-2 antibodies | |
WO2011131746A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
EP2636642A4 (en) | Cnt dispersion liquid, cnt compact, cnt composition, cnt assembly, and method for producing each | |
IL212066A (en) | Anti cxcr4 antibodies, compositions comprising them, processes for their production and selection and use thereof | |
EP2334330A4 (en) | Anti-cd147 antibodies, methods, and uses | |
MX2010007716A (en) | COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART. | |
LT2510012T (en) | Anti-c4.4a antibodies and uses thereof | |
WO2009111586A3 (en) | Autonomous in vitro evolution | |
WO2010136483A3 (en) | Antigen-binding proteins | |
HK1181056A1 (en) | Atelocollagen separation method, method for preparing modified atelocollagen, and atelocollagen-and collagen-based matrix prepared by the methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09715242 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009715242 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |